Genprex shares surge 14.98% after-hours on Congressman Tim Moore's investment and FDA meeting for REQORSA.

Genprex Inc. surged 14.98% in after-hours trading, driven by positive developments including Congressman Tim Moore’s investment of $31,000–$115,000, signaling confidence in its lead drug candidate REQORSA and upcoming FDA meetings for human clinical trials. The stock also gained momentum from preclinical data showing GPX-002’s potential to normalize glucose levels in diabetes models, alongside relief over meeting Nasdaq’s equity requirements, eliminating delisting risks. These factors—strategic investor backing, regulatory progress, and therapeutic advancements—collectively fueled heightened investor interest and volatility in the after-hours session.